Compounds > oxazoles
Page last updated: 2024-08-21

oxazoles and Cancer of Esophagus

oxazoles has been researched along with Cancer of Esophagus in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chen, L; Fang, D; Song, Y; Wang, C; Xie, S; Yang, H; Zeng, H; Zhao, Z1
Cao, HH; Chen, B; Chen, H; Du, ZP; Huang, W; Jia, W; Jiang, H; Li, EM; Li, LY; Liao, LD; Xie, JJ; Xie, YM; Xu, LY; Xu, XE; Zeng, FM; Zhang, YL; Zheng, W1
Ding, Y; Hong, T; Imamura, M; Kaganoi, J; Kawabe, A; Komoto, I; Li, Z; Maeda, M; Sato, F; Shimada, Y1

Other Studies

3 other study(ies) available for oxazoles and Cancer of Esophagus

ArticleYear
Transcriptional inhibition by CDK7/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma.
    Cell death & disease, 2021, 11-05, Volume: 12, Issue:11

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Neoplasm Metastasis; Oxazoles; Thiazoles; Transcription, Genetic; Tumor Burden; Wound Healing

2021
Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking β1 integrin activation.
    Oncotarget, 2015, Jun-30, Volume: 6, Issue:18

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Integrin beta1; Male; Mice; Mice, Nude; Oxazoles; Random Allocation; Xenograft Model Antitumor Assays

2015
Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor.
    Carcinogenesis, 2001, Volume: 22, Issue:4

    Topics: Animals; Benzenesulfonates; Body Weight; Carcinogens; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dimethylnitrosamine; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Esophagus; Isoenzymes; Male; Oxazoles; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction

2001